UNLOCKING THE BODY’S NATURAL DEFENSES AGAINST CANCER
Manhattan BioSolutions is an emerging biotech company inventing novel precision biologics that harness the power of host-defense adaptations for the treatment of advanced cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues
Scientific Platforms
Degrader Nucleases
Developing a new generation of human nuclease therapeutics with potent anti-cancer activities. The RNA degrader (RNAD) platform utilizes engineered derivative of naturally occurring enzyme involved in host defense to selectively degrade RNA in tumors
ADCs
Developing novel biologics, Antibody-Drug Conjugates (ADCs) that target cell-surface receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms
In the News
